Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

NCT02345772 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped PI no longer at site. Data was not collected

Conditions

HER2-positive Breast Cancer
ER-positive Breast Cancer

Interventions

DRUG: fulvestrant 500 mg
DRUG: Docetaxel
DRUG: Trastuzumab (H, 8mg/kg
DRUG: Pertuzumab (P, 840 mg

Sponsor

Western Regional Medical Center